Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005012 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
A Phase 2 study, sponsored by Schering-Plough.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT00005012 is a Phase 2 study that has completed, run by Schering-Plough. The registered enrollment target is 250 participants.
The verdict
NCT00005012, a Phase 2 study, has completed, sponsored by Schering-Plough.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
Interventions
- DRUG Peginterferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2000-03 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005012
The ClinicalTrials.gov registry entry for NCT00005012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Schering-Plough, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peginterferon alfa-2b is the first listed.
NCT00005012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005012 about?
NCT00005012 is a clinical study titled "Safety and Effectiveness of PEG-Intron in HIV-Infected Patients". The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
What is the current status of trial NCT00005012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2000-03. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00005012?
The interventions under investigation include: Peginterferon alfa-2b (DRUG).
Who is sponsoring clinical trial NCT00005012?
This trial is sponsored by Schering-Plough, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.